Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial

Thrombosis Journal

Table 1 Baseline characteristics (on study day) of healthy subjects included in this trial

Baseline characteristics	Median (IQR)	001	002	003	004	005	006	007	008	009	010	011	012
Age - years	32 (24.5–40.5)	24	26	29	41	31	51	39	22	21	56	33	35
Female sex [no.]	4 (8 males)	0	1	1	1	1	0	0	0	0	0	0	0
Weight - kilogram	69 (59–77)	76	58	60	59	58	70	76	68	77	86	64	91,5
Ethnicity	caucasian = c, black = b, asian = a	c	c	c	c	c	b	c	a	c	c	c	c
Vital parameters
RR systolic - mmHg	133 (128–146)	147	107	129	112	136	143	147	128	130	157	140	128
RR diastolic - mmHg	79 (73–88.5)	80	68	78	72	87	97	95	76	78	89	71	82
Heart rate - bpm	79 (70–84)	80	82	61	53	79	87	69	84	78	76	84	74
SpO₂ - %	98 (97–99)	99	99	100	99	98	95	97	98	98	98	99	97
Temperature (axilla) – degree celsius (°C)	36.0 (35.6–36.1)	35,8	36,4	36	36,1	36,3	35,7	35,5	35	35,5	36,0	36,0	35,9
PLT count (× 10⁹)^a	263 (224–281)	285	291	219	281	280	160	240	247	256	216	270	276
MEA ADP - U	68 (59–86)	74	68	96	73	99	39^b	62	58	60	51	90	68

PLT platelet, MEA multiple electrode aggregometry, ADP adenosine diphosphate, RR Riva-Rocci ≈ blood pressure, bpm beats per minute, SpO2 peripheral oxygen saturation, IQR interquartile range)
^a Measured at screening visit
^b Healthy subject 006 presented with an initial ADP-induced platelet aggregation of 39 U, which is already within the therapeutic range. ADP-induced platelet aggregation re-increased to 50 U at 60 min after the first bolus infusion of cangrelor and peaked at 64 U just before the following cangrelor bolus infusion. Potential causes of the initial low level of ADP-induced platelet aggregation could involve a false-low measurement or diurnal variation of platelet function. ADP-induced platelet aggregation is also influenced by variations in platelet count, even within the physiological range [44]

ISSN: 1477-9560